A nationwide experience of biological treatments in children with eosinophilic esophagitis
Authors:
Open Access
- 7 June 2025
- journal article
- research article
- Published by Springer Nature in Pediatric Research
- p. 1-9
Abstract
Background: No biological treatment has been approved for pediatric eosinophilic esophagitis (EoE) in France. For patients refractory to conventional treatments, although compassionate use of monoclonal antibodies has developed, experience remains limited. Methods: We conducted a national multicenter study across French pediatric tertiary care centers where children (younger than 18 years) who presented with EoE were treated with biological therapies between January 2015 and December 2023. The main objective was to characterize this patient population, and the indications for prescribing biologics. The secondary goals were to assess these patients’ clinical, endoscopic, and histologic finding, as well as patient tolerance, and to compare our cohort at baseline with pediatric patients from two European registers of EoE treated with conventional therapies. Results: Thirty-six patients were prescribed 37 biologics (omalizumab, n = 1; mepolizumab, n = 6; dupilumab, n = 30). At diagnosis, the mean patient age was 7.4 (±4.4) years, and most patients had at least one atopic comorbidity (91.7%, n = 33). Failure of first-line treatments was the main reason for starting biological therapy (75.7%, n = 28), prescribed as compassionate use (54.1%, n = 20). Dupilumab showed significant clinical (48%, p < 0.01) and histological (82.6%, p < 0.01) improvement. Compared with children treated with conventional therapies, patients in our cohort at baseline presented significantly more asthma, food allergies, and atopic dermatitis, as well as more fibrostenotic phenotype and digestive symptoms. No severe side effect was reported within a 6–12-month follow-up. Conclusion: Dupilumab is the most frequently prescribed, and appears to be the most effective biotherapy, regarding clinical and histologic remission. All biologics were well-tolerated. Impact: Pending marketing authorization, biological therapies for pediatric eosinophilic esophagitis are mainly prescribed after failure of first-line treatments and on a compassionate basis in France. Dupilumab is the biotherapy most frequently used, is associated with clinical and histological efficacy and is well-tolerated. Children and adolescents requiring biologics appear to be younger and more severe at diagnosis than naive pediatric patients in Europeans registries.Keywords
This publication has 32 references indexed in Scilit:
- Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)Journal of Pediatric Gastroenterology and Nutrition, 2024
- Maternal and Infant Antibiotic and Acid Suppressant Use and Risk of Eosinophilic EsophagitisJAMA Pediatrics, 2023
- Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2023
- Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registryDigestive and Liver Disease, 2022
- Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate useAnnals of Allergy, Asthma & Immunology, 2022
- Environmental factors and eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2018
- Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2018
- Genetics of eosinophilic esophagitisMucosal Immunology, 2017
- Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysisAnnals of Allergy, Asthma & Immunology, 2014
- Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2014